Cell No. : Cell Name
RCB3676 : 5637
update : 2024/08/14
|
| Comment | Human cell line derived from bladder carcinoma. TKG0605 (Deposited from Tohoku Univ.). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Fukuda, Hiroshi
|
| Originator |
Cannon G.
|
| Year of deposit |
2011
|
| Original cell |
TKG0605
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Male
|
| Age at sampling |
68 years
|
| Tissue |
bladder
|
| Disease name |
Bladder carcinoma
|
| Classification |
cancer
|
| History |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0605）
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_0126
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.02% EDTA-PBS
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Animal PCR |
|
OK
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
11
|
| User's Publication |
2
|
| Reference |
|
4954
Quentmeier H, Zaborski M, Drexler HG.
The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines.
Leuk Res
1997
21(4):343-50
PubMed ID: 9150352
DOI: 10.1016/s0145-2126(96)00132-4
|
|
2040
Bailly JD, Pourquier P, Jaffrézou JP, Duchayne E, Cassar G, Bordier C, Laurent G.
Effect of 5637-conditioned medium and recombinant cytokines on P-glycoprotein expression in a human GM-CSF-dependent leukemic myeloid cell line
Leukemia
1995
9(10):1718-25
PubMed ID: 7564516
|
|
4953
Kaashoek JG, Mout R, Falkenburg JH, Willemze R, Fibbe WE, Landegent JE.
Cytokine production by the bladder carcinoma cell line 5637: rapid analysis of mRNA expression levels using a cDNA-PCR procedure.
Lymphokine Cytokine Res
1991
10(3):231-5
PubMed ID: 1883917
|
|
2039
Borinaga AM, Millar BC, Bell JB, Joffe JK, Millar JL, Gooding R, Riches P, McElwain TJ.
Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro
Br J Haematol
1990
76(4):476-83
PubMed ID: 2265109
DOI: 10.1111/j.1365-2141.1990.tb07903.x
|
|
2038
Tennant GB, Jacobs A.
Effect of 5637-conditioned medium on peripheral blood granulocyte-macrophage progenitors in normal subjects and patients with the myelodysplastic syndrome
Leuk Res
1989
385-9
PubMed ID: 2787448
DOI: 10.1016/0145-2126(89)90078-7
|
|
2036
Miyauchi J, Kelleher CA, Yang YC, Wong GG, Clark SC, Minden MD, Minkin S, McCulloch EA.
The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture.
Blood
1987
70(3):657-63
PubMed ID: 3304459
|
|
2037
Asano Y, Shibuya T, Okamura S, Morioka E, Taniguchi S, Niho Y.
Synergism of leukemic blast growth factors in medium conditioned by human bladder carcinoma cell line 5637.
Int J Cell Cloning
1987
5(6):504-10
PubMed ID: 3480913
DOI: 10.1002/stem.5530050608
|
|
2035
Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R, Moore MA.
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.
Proc Natl Acad Sci U S A
1985
82(5):1526-30
PubMed ID: 3871951
DOI: 10.1073/pnas.82.5.1526
|
|
5464
Welte K, Platzer E, Gabrilove JL, Lu L, Levi E, Polivka A, Mertelsmann R, Moore MA.
Purification to apparent homogeneity and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.
Haematol Blood Transfus
1985
29:398-401
PubMed ID: 3875526
DOI: 10.1007/978-3-642-70385-0_82
|
|
4956
Myers CD, Katz FE, Joshi G, Millar JL.
A cell line secreting stimulating factors for CFU-GEMM culture.
Blood
1984
64(1):152-5
PubMed ID: 6733267
|
|
3355
Fogh J.
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Natl Cancer Inst Monogr
1978
49:5-9.
PubMed ID: 571047
|
| User's Publication |
|
21489
Myoen S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, Shindo N, Yamaguchi K, Yasuda J, Abe J, Imai T, Sato I, Adachi H, Kawamura S, Ito A, Tamai K.
CD271 promotes proliferation and migration in bladder cancer.
Genes Cells
2023
PubMed ID: 38016691
DOI: 10.1111/gtc.13087
|
|
14268
Yamashita T, Higashi M, Momose S, Morozumi M, Tamaru JI.
Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer
Int J Oncol
2017
51(2):579-586
PubMed ID: 28714514
DOI: 10.3892/ijo.2017.4031
|
Back
Top
CELL BANK Website
